ライフサイエンスコーパス: FABP7

1 ro (P0) and/or fatty acid binding protein 7 (Fabp7).

2 pregulation of fatty acid-binding protein 7 (Fabp7).

3 otein (FABP) family genes (FABP1, FABP4, and FABP7).

4 in strongly reduced expression of Sox10 and Fabp7.

5 gh Sox10 levels and to trigger expression of Fabp7.

6 -induced genes, including Itga5, Olfml3, and Fabp7.

7 in with characteristics distinct from native FABP7.

8 FABP7, a brain-FABP, maintains metabolic function in ast

9 melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (P<0

10 Fabp7 also improves mitochondrial function and fatty aci

11 ic analysis as fatty acid binding protein 7 (FABP7), also known as brain lipid binding protein) which

12 of the neurodevelopmentally important genes FABP7 and GAD1.

13 he brain fatty acid-binding protein (B-FABP; FABP7) and glial fibrillary acidic protein (GFAP) genes

14 ratory factors fatty acid-binding protein 7 (FABP7) and Ras homolog family member A (RHOA).

15 s, CSDE1 binds fatty acid binding protein 7 (FABP7) and vimentin (VIM) mRNAs, as well as transcripts

16 urther investigated one gene from the group, FABP7, and confirmed its association with survival in tw

17 central nervous system (FABP3, FABP4, FABP5, FABP7, and PMP2).

18 Together, our results support FABP7 as a potential target for the treatment of HER2+ B

19 FABP7 as a surrogate biomarker for circulating tumor cel

20 stoma cells after overexpression of FABP5 or FABP7, but not FABP3.

21 L cell line proliferation and growth on LTR2-FABP7 chimeric protein expression.

22 The LTR2-FABP7 chimeric transcript encodes a novel chimeric isofo

23 ased levels of fatty acid-binding protein 7 (FABP7) correlate with a lower survival and higher incide

24 Targeting Fabp7 could enhance immunotherapy effectiveness by re-se

25 Assessment of patients' blood showed that FABP7(+) CTC decreased with disease progression.

26 Fabp7 decreases the transcription of ferroptosis-inducin

27 FABP7 detection of metastatic tissues was inversely corr

28 PD1-resistant tumors upregulate Fabp7, driving protective metabolic changes that shield

29 Expression of FABP7 enhanced the motility of glioma-derived cells in v

30 Clinical trial data revealed that higher FABP7 expression correlates with poorer overall survival

31 Furthermore, cancer cells increase Fabp7 expression in CD8(+) T cells, disrupting circadian

32 Given that Fabp7 expression is confined to astrocytes and neural pr

33 To examine FABP7 expression loss in advanced melanomas, loss of het

34 sing microsatellite markers encompassing the FABP7 gene.

35 Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melan

36 astrocyte brain fatty acid binding protein (Fabp7) has previously been shown to have a coordinated d

37 ng proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellu

38 Our results uncover a key role of FABP7 in metabolic reprogramming of HER2 + breast cancer

39 ression assays, we characterized the role of FABP7 in the BCBM process in vitro and in vivo.

40 Here we find elevated levels of FABP7 in the serum and cerebrospinal fluid of patients w

41 Lipidomic profiling revealed that Fabp7 increases triglycerides and monounsaturated fatty

42 FABP7-induced gene expression reflects enhanced inflamma

43 Mechanistically, in vitro treatment of FABP7 induces CD16, CD80 and IL-1beta expression in mono

44 In conclusion, we find that FABP7 induces pro-inflammatory profiles in monocytes, co

45 hat brain-expressed FABPs (FABP3, FABP5, and FABP7) interact with epoxyeicosatrienoic acids (EETs) an

46 During development, FABP7 is highly expressed by retinal progenitor cells an

47 In addition, FABP7 is shown to be required for upregulation of key me

48 FABP7 levels are increased in astrocytes from MS postmor

49 Elevated serum FABP7 levels positively correlate with higher disability

50 e expression in cancer and suggest that LTR2-FABP7 may contribute to the pathogenesis of DLBCL in a s

51 FABP7 may function as a tumor progression gene and can b

52 In this study, we confirmed an enrichment of Fabp7 mRNA and protein in the astrocytic perisynaptic co

53 Here we show that Fabp7 mRNA coimmunoprecipitated with CPEB1 from primary

54 change in the intracellular distribution of Fabp7 mRNA in molecular layers of hippocampus.

55 lar trafficking and localized translation of Fabp7 mRNA in the tripartite synapse of mammalian brain.

56 e brain, the synchronized cycling pattern of Fabp7 mRNA is a novel discovery among known CPE-regulate

57 ed time-of-day-dependent oscillation for the Fabp7 mRNA poly(A) tail throughout murine brain.

58 FABP7 mRNA was highly expressed in 60 of 87 (69%) primar

59 ving a fatty acid-binding protein gene (LTR2-FABP7), normally expressed in brain, that was ectopicall

60 tes and neural stem cells, but the effect of FABP7 on monocytes is unknown.

61 d 12 (Cxcl12), fatty acid binding protein 7 (Fabp7), plasma membrane proteolipid (Pllp), and suppress

62 n (CLDN1/CLDN8), and lipid metabolism (FA2H, FABP7)-related markers.

63 of-day changes in expression and trafficking Fabp7 to the perisynaptic process are not known.

64 ls evade immune-mediated ferroptosis through Fabp7 upregulation.

65 Expression of FABP7 was assessed during melanoma progression through a

66 racted with FABP3 and FABP5 while binding to FABP7 was markedly lower.

67 ily of genes, specifically FABP1, FABP4, and FABP7, was also observed to be synergistically upregulat

68 observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets.